<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="d2d71458-ab2e-4d49-b988-481f0764f9df"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use </content>
      <content styleCode="bold">METHYLPHENIDATE HYDROCHLORIDE ORAL SOLUTION safely and
effectively. <br/>
See full prescribing information for <content styleCode="bold">METHYLPHENIDATE HYDROCHLORIDE ORAL SOLUTION</content>.
</content>
      <content styleCode="bold"/>
      <content styleCode="bold">
         <br/>
      </content>
      <content styleCode="bold">
         <br/>
         <content styleCode="bold">METHYLPHENIDATE HYDROCHLORIDE Oral Solution, CII</content>
         <br/>
      </content>
      <content styleCode="bold">Initial U.S. Approval: 1955</content>
   </title>
   <effectiveTime value="20240403"/>
   <setId root="ad3a3865-952e-46cf-8387-1228e2375312"/>
   <versionNumber value="102"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="171714327" root="1.3.6.1.4.1.519.1"/>
            <name>Bryant Ranch Prepack</name>
            <assignedEntity>
               <assignedOrganization>
                  <id extension="171714327" root="1.3.6.1.4.1.519.1"/>
                  <name>Bryant Ranch Prepack</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="171714327" root="1.3.6.1.4.1.519.1"/>
                        <name>Bryant Ranch Prepack</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73606" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="REPACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code codeSystem="2.16.840.1.113883.6.69" code="72162-2040"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C73607" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="RELABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code codeSystem="2.16.840.1.113883.6.69" code="72162-2040"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="f0971e50-d8d5-4227-b05d-f9e7ab8b2df1"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20240416"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="72162-2040" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Methylphenidate Hydrochloride</name>
                        <formCode code="C42986" displayName="SOLUTION" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Methylphenidate Hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="27808-058" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="5"/>
                              <denominator unit="mL" value="5"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4B3SC438HI" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHYLPHENIDATE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="207ZZ9QZ49" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>METHYLPHENIDATE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="PDC6A3C0OX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OJ4Z5Z32L4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 1450</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6X543N684K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GRAPE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="500" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="72162-2040-5" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20240403"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA091601" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20150304"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLFLAVOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C73391" displayName="GRAPE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" displayName="CII" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </policy>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <component>
                  <observationMedia ID="MM1">
                     <text>methylphenidatestructure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="methylphenidate-hydrochloride-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_f03a6409-0357-465b-9870-da6b225f99ec">
               <id root="fb58bfa3-5915-4be6-b1e7-514eca1d0f01"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <title/>
               <text/>
               <effectiveTime value="20231212"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <linkHtml href="#LINK_71aa10c1-67a4-45f5-9192-6214fe740012">Boxed Warning</linkHtml>                                                                                                              10/2023</paragraph>
                        <paragraph>Dosage and Administration (<linkHtml href="#LINK_0dc84223-47ee-4645-8772-a9b6cd568f5c">2.1</linkHtml>, <linkHtml href="#LINK_d91ab7e6-1d7c-4e12-a52c-afbd910f857b">2.2</linkHtml>, <linkHtml href="#LINK_d0524683-36fb-42e6-9378-4434403b9410">2.3</linkHtml>)                                                                    10/2023</paragraph>
                        <paragraph>Warnings and Precautions (<linkHtml href="#LINK_3b3b21c5-29f6-4f62-88af-5ae5837a4bd1">5.1</linkHtml>, <linkHtml href="#LINK_87a0e526-65fe-43e4-9fe6-69c7a31ef9cb">5.2</linkHtml>, <linkHtml href="#LINK_49d34866-aeef-47c8-bd84-a16c94114a15">5.8</linkHtml>, <linkHtml href="#LINK_4bb472b7-1eb3-486b-9601-b519ffc4be81">5.9</linkHtml>, <linkHtml href="#LINK_3a521fb2-da03-4234-a43c-8334c70f4306">5.10</linkHtml>)                                                      10/2023</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_71aa10c1-67a4-45f5-9192-6214fe740012">
               <id root="32077744-5398-41cd-9ae2-22955fff05b0"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>
                  <content styleCode="bold">
                     <content styleCode="xmChange">WARNING:  ABUSE, MISUSE, AND ADDICTION</content>
                  </content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="xmChange">
                        <content styleCode="bold">Methylphenidate hydrochloride oral solution has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including methylphenidate hydrochloride, can result in overdose and death <content styleCode="italics">[see Overdosage (</content>
                        </content>
                        <content styleCode="bold">
                           <content styleCode="italics">
                              <linkHtml href="#LINK_bc3ddadb-3b0b-4cf1-b5d0-12ff357b4879">10</linkHtml>
                           </content>
                        </content>
                        <content styleCode="bold">
                           <content styleCode="italics">)]</content>
                        </content>
                        <content styleCode="bold">, and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="xmChange">
                        <content styleCode="bold">Before prescribing methylphenidate hydrochloride oral solution, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout methylphenidate hydrochloride oral solution treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction <content styleCode="italics">[see Warnings and Precautions (</content>
                        </content>
                        <content styleCode="bold">
                           <content styleCode="italics">
                              <linkHtml href="#LINK_3b3b21c5-29f6-4f62-88af-5ae5837a4bd1">5.1</linkHtml>
                           </content>
                        </content>
                        <content styleCode="bold">
                           <content styleCode="italics">) and Drug Abuse and Dependence (</content>
                        </content>
                        <content styleCode="bold">
                           <content styleCode="italics">
                              <linkHtml href="#LINK_5fd1405d-143a-439f-a237-b2315c293c33">9.2</linkHtml>
                           </content>
                        </content>
                        <content styleCode="bold">
                           <content styleCode="italics">)]</content>. </content>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20231212"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING:  ABUSE, MISUSE, AND ADDICTION</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Methylphenidate hydrochloride oral solution has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including methylphenidate hydrochloride oral solution, can result in overdose and death (</content>
                           <content styleCode="bold">
                              <linkHtml href="#LINK_3b3b21c5-29f6-4f62-88af-5ae5837a4bd1">5.1</linkHtml>
                           </content>
                           <content styleCode="bold">, </content>
                           <content styleCode="bold">
                              <linkHtml href="#LINK_5fd1405d-143a-439f-a237-b2315c293c33">9.2</linkHtml>
                           </content>
                           <content styleCode="bold">, </content>
                           <content styleCode="bold">
                              <linkHtml href="#LINK_bc3ddadb-3b0b-4cf1-b5d0-12ff357b4879">10</linkHtml>
                           </content>
                           <content styleCode="bold">):</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="bold">Before prescribing methylphenidate hydrochloride oral solution, assess each patient’s risk for abuse, misuse, and addiction.</content>
                           </item>
                           <item>
                              <content styleCode="bold">Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug.</content>
                           </item>
                           <item>
                              <content styleCode="bold">Throughout treatment, reassess each patient’s risk and frequently monitor for signs and symptoms of abuse, misuse, and addiction.</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_f3bb862a-af1e-4fbd-99fb-9c45bff83072">
               <id root="f754409e-fd24-43e6-8826-8d9c13e36ad1"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>
                  <content styleCode="bold">1 INDICATIONS AND USAGE</content>
               </title>
               <text>
                  <paragraph>Methylphenidate hydrochloride oral solution is indicated for the treatment of:</paragraph>
                  <paragraph>• Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years of age and older</paragraph>
                  <paragraph>• Narcolepsy</paragraph>
               </text>
               <effectiveTime value="20231212"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Methylphenidate hydrochloride oral solution is a central nervous system (CNS) stimulant indicated for the treatment of:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years of age and older (<linkHtml href="#LINK_f3bb862a-af1e-4fbd-99fb-9c45bff83072">1</linkHtml>)</item>
                           <item>Narcolepsy (<linkHtml href="#LINK_f3bb862a-af1e-4fbd-99fb-9c45bff83072">1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_ef52949f-e4dd-4c45-b7ab-fbbd280a9d85">
               <id root="6efaed91-f893-4458-b73a-ee6cd6b95e6b"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>
                  <content styleCode="bold">2 DOSAGE AND ADMINISTRATION</content>
               </title>
               <text/>
               <effectiveTime value="20231212"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Pediatric patients 6 years and older:</content> Starting dose is 5 mg twice daily (before breakfast and lunch); increase the dose 5 mg to 10 mg weekly; daily dosage above 60 mg is not recommended. (<linkHtml href="#LINK_d91ab7e6-1d7c-4e12-a52c-afbd910f857b">2.2</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Adults:</content> Administer in divided doses 2 or 3 times daily, preferably 30 to 45 minutes before meals. Average dosage is 20 to 30 mg daily. Maximum recommended daily dosage is 60 mg. (<linkHtml href="#LINK_ef52949f-e4dd-4c45-b7ab-fbbd280a9d85">2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_0dc84223-47ee-4645-8772-a9b6cd568f5c">
                     <id root="ec696b7b-9a04-4d32-855f-a03ffef19ddf"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.1 Pretreatment
Screening</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Prior to treating patients with methylphenidate hydrochloride oral solution, assess:</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>
                              <content styleCode="xmChange">for the presence of cardiac disease (i.e., perform a careful history, family history of sudden death or ventricular arrhythmia, and physical exam) <content styleCode="italics">[see Warnings and Precautions (</content>
                                 <content styleCode="italics">
                                    <linkHtml href="#LINK_87a0e526-65fe-43e4-9fe6-69c7a31ef9cb">5.2</linkHtml>
                                 </content>
                                 <content styleCode="italics">)]</content>.</content>
                           </item>
                           <item>
                              <content styleCode="xmChange">the family history and clinically evaluate patients for motor or verbal tics or Tourette’s syndrome <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_3a521fb2-da03-4234-a43c-8334c70f4306">5.10</linkHtml>)]</content>.</content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20231212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_d91ab7e6-1d7c-4e12-a52c-afbd910f857b">
                     <id root="65b7d10b-924a-4360-8e45-640bb5f7feb5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.2 General
Dosing Information</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange underline">Pediatric Patients 6 years of Age and Older</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">The recommended starting dosage is 5 mg orally twice daily before breakfast and lunch (preferably 30 to 45 minutes before meals). Increase the dosage gradually, in increments of 5 mg to 10 mg weekly.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Daily dosage above 60 mg is not recommended.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange underline">Adults </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Administer orally in divided doses 2 or 3 times daily, preferably 30 to 45 minutes before meals. The maximum recommended daily dose is 60 mg. The average dosage is 20 to 30 mg daily. For adult patients who are unable to sleep if medication is taken late in the day, administer the last dose before 6 p.m.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_d0524683-36fb-42e6-9378-4434403b9410">
                     <id root="9ec30560-17d5-4f5a-9f1d-095cf3ea1010"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.3 Dosage
Reduction and Discontinuation</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">If paradoxical aggravation of symptoms or other adverse reactions occur, reduce dosage, or, if necessary, discontinue methylphenidate hydrochloride oral solution. If improvement is not observed after appropriate dosage adjustment over a one-month period, discontinue methylphenidate hydrochloride oral solution.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231212"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_548dd1ea-2a97-4df9-b0bb-b24380dc2cbf">
               <id root="ab452566-a2be-4f5e-b150-ea3269c20c2c"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>
                  <content styleCode="bold">3 DOSAGE FORMS AND STRENGTHS</content>
               </title>
               <text>
                  <paragraph>Methylphenidate hydrochloride oral solution is a colorless, grape flavored liquid available in a 500 mL bottle in the following strengths:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>5 mg per 5 mL</item>
                     <item>10 mg per 5 mL</item>
                  </list>
               </text>
               <effectiveTime value="20231212"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Oral solution:</content> 5 mg per 5 mL and 10 mg per 5 mL. (<linkHtml href="#LINK_548dd1ea-2a97-4df9-b0bb-b24380dc2cbf">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_cf0d4f74-036e-4cee-856c-f1616c7f0274">
               <id root="ace03446-890d-4e86-b249-3010b5a8e4a5"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>
                  <content styleCode="bold">4 CONTRAINDICATIONS</content>
               </title>
               <text>
                  <paragraph>Methylphenidate hydrochloride oral solution is contraindicated in patients:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>with known hypersensitivity to methylphenidate or other components of methylphenidate hydrochloride oral solution. Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with methylphenidate <content styleCode="italics">[see Adverse Reactions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#final%20labeling%20text%20-%20PLR%20-%20Sharma_nl.docx#Adverse_Reactions">6</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>.</item>
                     <item>receiving concomitant treatment with monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOI, because of the risk of hypertensive crises <content styleCode="italics">[see Drug Interactions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#final%20labeling%20text%20-%20PLR%20-%20Sharma_nl.docx#Drug_Interactions">7</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>.</item>
                  </list>
               </text>
               <effectiveTime value="20210826"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Known hypersensitivity to methylphenidate or other components of methylphenidate hydrochloride oral solution (<linkHtml href="#final%20labeling%20text%20-%20PLR%20-%20Sharma_nl.docx#Contraindications">4</linkHtml>)</item>
                           <item>Concurrent treatment with a monoamine oxidase inhibitor (MAOI), or use of an MAOI within the preceding 14 days (<linkHtml href="#final%20labeling%20text%20-%20PLR%20-%20Sharma_nl.docx#Contraindications">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_646f0c1a-88d4-4c02-8f2a-488fbf6356b0">
               <id root="f7d23c69-ccc1-49ef-b481-5b9d911a306a"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>
                  <content styleCode="bold">5 WARNINGS AND PRECAUTIONS</content>
               </title>
               <text/>
               <effectiveTime value="20231214"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Risks to Patients with Serious Cardiac Disease:</content> Avoid use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmias, coronary artery disease, or other serious cardiac disease. (<linkHtml href="#LINK_87a0e526-65fe-43e4-9fe6-69c7a31ef9cb">5.2</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Increased Blood Pressure and Heart Rate:</content> Monitor blood pressure and pulse. (<linkHtml href="#LINK_8ee60d7b-2bac-45d4-b0f8-6337633f9058">5.3</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Psychiatric Adverse Reactions:</content> Prior to initiating methylphenidate hydrochloride oral solution, screen patients for risk factors for developing a manic episode. If new psychotic or manic symptoms occur, consider discontinuing methylphenidate hydrochloride oral solution. (<linkHtml href="#LINK_e1d6e8c2-3cd1-470d-86f6-d848b148569e">5.4</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Priapism:</content> If abnormally sustained or frequent and painful erections occur, patients should seek immediate medical attention. (<linkHtml href="#LINK_9dfd199a-670f-4709-8ce5-85e3e9c5a04f">5.5</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Peripheral Vasculopathy, Including Raynaud’s Phenomenon:</content> Careful observation for digital changes is necessary during methylphenidate hydrochloride treatment. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for patients who develop signs or symptoms of peripheral vasculopathy. (<linkHtml href="#LINK_8be87854-d140-470f-bbea-ead5d9232af2">5.6</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Long-Term Suppression of Growth in Pediatric Patients:</content> Closely monitor (height and weight) in pediatric patients. Pediatric patients not growing or gaining height or weight as expected may need to have their treatment interrupted. (<linkHtml href="#LINK_99d54a3a-fe88-4f54-91b0-02e8d8155e0e">5.7</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Acute Angle Closure Glaucoma:</content> Methylphenidate hydrochloride-treated patients considered at risk for acute angle closure glaucoma (e.g., patients with significant hyperopia) should be evaluated by an ophthalmologist. (<linkHtml href="#LINK_49d34866-aeef-47c8-bd84-a16c94114a15">5.8</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Increased Intraocular Pressure (IOP) and Glaucoma:</content> Prescribe methylphenidate hydrochloride oral solution to patients with open-angle glaucoma or abnormally increased IOP only if the benefit of treatment is considered to outweigh the risk. Closely monitor patients with a history of increased IOP or open-angle glaucoma. (<linkHtml href="#LINK_4bb472b7-1eb3-486b-9601-b519ffc4be81">5.9</linkHtml>)</item>
                           <item>
                              <content styleCode="italics">Motor and Verbal Tics, and Worsening of Tourette’s Syndrome:</content> Before initiating methylphenidate hydrochloride oral solution, assess the family history and clinically evaluate patients for tics or Tourette’s syndrome. Regularly monitor patients for the emergence or worsening of tics or Tourette’s syndrome. Discontinue treatment if clinically appropriate. (<linkHtml href="#LINK_3a521fb2-da03-4234-a43c-8334c70f4306">5.10</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_3b3b21c5-29f6-4f62-88af-5ae5837a4bd1">
                     <id root="eab89a63-5888-4003-add6-727e74683438"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.1 Abuse, Misuse, and Addiction</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Methylphenidate hydrochloride oral solution has a high potential for abuse and misuse. The use of methylphenidate hydrochloride exposes individuals to the risks of abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Methylphenidate hydrochloride oral solution can be diverted for non-medical use into illicit channels or distribution <content styleCode="italics">[see Drug Abuse and Dependence (<linkHtml href="#LINK_5fd1405d-143a-439f-a237-b2315c293c33">9.2</linkHtml>)]</content>. Misuse and abuse of CNS stimulants, including methylphenidate hydrochloride, can result in overdose and death <content styleCode="italics">[see Overdosage (<linkHtml href="#LINK_bc3ddadb-3b0b-4cf1-b5d0-12ff357b4879">10</linkHtml>)]</content>, and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Before prescribing methylphenidate hydrochloride oral solution, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks and proper disposal of any unused drug. Advise patients to store methylphenidate hydrochloride oral solution in a safe place, preferably locked, and instruct patients to not give methylphenidate hydrochloride oral solution to anyone else. Throughout methylphenidate hydrochloride treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_87a0e526-65fe-43e4-9fe6-69c7a31ef9cb">
                     <id root="1bfadce0-eee1-4d7f-9f82-28aad38319d4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.2 Risks to Patients with Serious Cardiac Disease</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Sudden death has been reported in patients with structural cardiac abnormalities or other serious cardiac disease who were treated with CNS stimulants at the recommended ADHD dosage.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Avoid methylphenidate hydrochloride use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrythmia, coronary artery disease, or other serious cardiac disease.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_8ee60d7b-2bac-45d4-b0f8-6337633f9058">
                     <id root="c1447735-2738-467b-9a4c-2932ba44b09b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.3 Increased Blood Pressure and Heart Rate </content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">CNS stimulants cause an increase in blood pressure (mean increase approximately 2 to 4 mmHg) and heart rate (mean increase approximately 3 to 6 bpm). Some patients may have larger increases. </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Monitor all methylphenidate hydrochloride-treated patients for hypertension and tachycardia.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_e1d6e8c2-3cd1-470d-86f6-d848b148569e">
                     <id root="4a0cf04a-fc5f-480d-a901-6321b89bc988"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.4 Psychiatric Adverse Reactions</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Exacerbation of Pre-Existing Psychosis</content>
                        </paragraph>
                        <paragraph>CNS stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Induction of a Manic Episode in Patients with Bipolar Illness</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">CNS stimulants may induce a manic or mixed mood episode in patients. Prior to initiating methylphenidate hydrochloride treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, or depression).</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange underline">New Psychotic or Manic Symptoms</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">CNS stimulants, at the recommended dosages, may cause psychotic or manic symptoms (e.g., hallucinations, delusional thinking, or mania) in patients without a prior history of psychotic illness or mania. In a pooled analysis of multiple short-term, placebo-controlled studies of CNS stimulants, psychotic or manic symptoms occurred in approximately 0.1% of CNS stimulant-treated patients, compared with 0% of placebo-treated patients. If such symptoms occur, consider discontinuing methylphenidate hydrochloride oral solution.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_9dfd199a-670f-4709-8ce5-85e3e9c5a04f">
                     <id root="116553b8-bc36-42ae-9b43-d196203f872e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.5 Priapism</content>
                     </title>
                     <text>
                        <paragraph>Prolonged and painful erections, sometimes requiring surgical intervention, have been reported with methylphenidate use in both adult and pediatric male patients. Although priapism was not reported with methylphenidate initiation, it developed after some time on methylphenidate, often subsequent to an increase in dosage. Priapism also occurred during methylphenidate withdrawal (drug holidays or during discontinuation). </paragraph>
                        <paragraph>Methylphenidate hydrochloride-treated patients who develop abnormally sustained or frequent and painful erections should seek immediate medical attention.</paragraph>
                     </text>
                     <effectiveTime value="20231212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_8be87854-d140-470f-bbea-ead5d9232af2">
                     <id root="97a6ff7d-b6ef-4ab5-b3b4-5d830e1f5bcb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.6 Peripheral
Vasculopathy, Including Raynaud’s Phenomenon</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">CNS stimulants, including methylphenidate hydrochloride oral solution, used to treat ADHD are associated with peripheral vasculopathy, including Raynaud’s phenomenon. Signs and symptoms are usually intermittent and mild; however, sequelae have included digital ulceration and/or soft tissue breakdown. Effects of peripheral vasculopathy, including Raynaud’s phenomenon, were observed in postmarketing reports and at the therapeutic dosages of CNS stimulants in all age groups throughout the course of treatment. Signs and symptoms generally improved after dosage reduction or discontinuation of the CNS stimulant. </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Careful observation for digital changes is necessary during methylphenidate hydrochloride treatment. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for methylphenidate hydrochloride-treated patients who develop signs or symptoms of peripheral vasculopathy.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_99d54a3a-fe88-4f54-91b0-02e8d8155e0e">
                     <id root="0c2c5fa2-169c-4f98-bee6-8b0cd1cd38a9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.7 Long-Term
Suppression of Growth in Pediatric Patients</content>
                     </title>
                     <text>
                        <paragraph>CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients.</paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Careful follow-up of weight and height in children ages 7 to 10 years who were randomized to either methylphenidate or non-medication treatment groups over 14 months, as well as in naturalistic subgroups of newly methylphenidate-treated and non-medication-treated pediatric patients over 36 months (to the ages of 10 to 13 years), suggests that pediatric patients who received methylphenidate for 7 days per week throughout the year had a temporary slowing in growth rate (on average, a total of about 2 cm less growth in height and 2.7 kg less growth in weight over 3 years), without evidence of growth rebound during this development period.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Closely monitor growth (weight and height) in methylphenidate hydrochloride-treated pediatric patients. Pediatric patients who are not growing or gaining height or weight as expected may need to have their treatment interrupted. The safety and effectiveness of methylphenidate hydrochloride oral solution have not been established in pediatric patient less than 6 years of age.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_49d34866-aeef-47c8-bd84-a16c94114a15">
                     <id root="9258d9f2-7b98-4f0c-8f9b-2421ca19cd48"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.8 Acute
Angle Closure Glaucoma</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">There have been reports of angle closure glaucoma associated with methylphenidate treatment. Although the mechanism is not clear, methylphenidate hydrochloride-treated patients considered at risk for acute angle closure glaucoma (e.g., patients with significant hyperopia) should be evaluated by an ophthalmologist.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_4bb472b7-1eb3-486b-9601-b519ffc4be81">
                     <id root="479669e8-29a4-4883-8c61-f3acde880906"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.9 Increased Intraocular Pressure and Glaucoma</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">There have been reports of an elevation of intraocular pressure (IOP) associated with methylphenidate treatment <content styleCode="italics">[see Adverse Reactions (</content>
                              <content styleCode="italics">
                                 <linkHtml href="#final-pi-text-lb8477-r03-122023_CLEAN.docx#Adverse_Reactions">6.2</linkHtml>
                              </content>
                              <content styleCode="italics">)].</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Prescribe methylphenidate hydrochloride oral solution to patients with open-angle glaucoma or abnormally increased IOP only if the benefit of treatment is considered to outweigh the risk. Closely monitor methylphenidate hydrochloride-treated patients with a history of abnormally increased IOP or open-angle glaucoma.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_3a521fb2-da03-4234-a43c-8334c70f4306">
                     <id root="4d554787-8911-4dce-ad87-1148b8ce9de8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.10 Motor and Verbal Tics, and Worsening of
Tourette’s Syndrome</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">CNS stimulants, including methylphenidate, have been associated with the onset or exacerbation of motor and verbal tics. Worsening of Tourette’s syndrome has also been reported <content styleCode="italics">[see Adverse Reactions (</content>
                              <content styleCode="italics">
                                 <linkHtml href="#final-pi-text-lb8477-r03-122023_CLEAN.docx#Adverse_Reactions">6.2</linkHtml>
                              </content>
                              <content styleCode="italics">)].</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Before initiating methylphenidate hydrochloride oral solution, assess the family history and clinically evaluate patients for tics or Tourette’s syndrome. Regularly monitor methylphenidate hydrochloride-treated patients for the emergence or worsening of tics or Tourette’s syndrome, and discontinue treatment if clinically appropriate.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20231214"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_eb8a0e30-63ca-4ced-84b8-8c5655f401dc">
               <id root="bea6ac74-22be-4844-ad99-8998a38cf8ea"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">6 ADVERSE REACTIONS</content>
               </title>
               <text>
                  <paragraph>The following adverse reactions are discussed in more detail in other sections of the labeling:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Abuse, misuse, and addiction <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_3b3b21c5-29f6-4f62-88af-5ae5837a4bd1">5.1</linkHtml>
                        </content>
                        <content styleCode="italics">), Drug Abuse and Dependence (</content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_5fd1405d-143a-439f-a237-b2315c293c33">9.2</linkHtml>
                        </content>
                        <content styleCode="italics">, </content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_6fcbeff3-254f-49c3-82f0-5a5eff279d8b">9.3</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>Known hypersensitivity to methylphenidate or other components of methylphenidate hydrochloride oral solution <content styleCode="italics">[see Contraindications (</content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_cf0d4f74-036e-4cee-856c-f1616c7f0274">4</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>Hypertensive crisis when used concomitantly with monoamine oxidase inhibitors <content styleCode="italics">[see Contraindications (</content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_cf0d4f74-036e-4cee-856c-f1616c7f0274">4</linkHtml>
                        </content>
                        <content styleCode="italics">), Drug Interactions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_5a356f49-8ad4-439a-927c-8ba01b943f01">7</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>Risks to patients with serious cardiac disease <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_87a0e526-65fe-43e4-9fe6-69c7a31ef9cb">5.2</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>Increased blood pressure and heart rate <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_8ee60d7b-2bac-45d4-b0f8-6337633f9058">5.3</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>Psychiatric adverse reactions <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_e1d6e8c2-3cd1-470d-86f6-d848b148569e">5.4</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>Priapism <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_9dfd199a-670f-4709-8ce5-85e3e9c5a04f">5.5</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>Peripheral vasculopathy, including Raynaud’s phenomenon <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_8be87854-d140-470f-bbea-ead5d9232af2">5.6</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>Long-term suppression of growth in pediatric patients <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#LINK_99d54a3a-fe88-4f54-91b0-02e8d8155e0e">5.7</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                     <item>Acute angle closure glaucoma <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_49d34866-aeef-47c8-bd84-a16c94114a15">5.8</linkHtml>)]</content>
                     </item>
                     <item>Increased intraocular pressure and glaucoma <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_4bb472b7-1eb3-486b-9601-b519ffc4be81">5.9</linkHtml>)]</content>
                     </item>
                     <item>Motor and verbal tics, and worsening of Tourette’s syndrome <content styleCode="italics">
                           <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_3a521fb2-da03-4234-a43c-8334c70f4306">5.10</linkHtml>)]</content>
                        </content>
                     </item>
                  </list>
                  <paragraph>The following adverse reactions associated with the use of methylphenidate containing products were identified in clinical studies, postmarketing reports, or literature. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Infections and infestations:</content> nasopharyngitis</paragraph>
                  <paragraph>
                     <content styleCode="italics">Blood and the lymphatic system disorders:</content> leukopenia, thrombocytopenia, anemia, pancytopenia</paragraph>
                  <paragraph>
                     <content styleCode="italics">Immune system disorders:</content> hypersensitivity reactions, including angioedema and anaphylaxis, auricular swelling, bullous conditions, eruptions, exanthemas</paragraph>
                  <paragraph>
                     <content styleCode="italics">Metabolism and nutrition disorders: </content>decreased appetite, reduced weight gain and suppression of growth during prolonged use in pediatric patients</paragraph>
                  <paragraph>
                     <content styleCode="italics">Psychiatric disorders: </content>insomnia, anxiety, restlessness, agitation, psychosis (sometimes with visual and tactile hallucinations), depressed mood, affect lability, mania, disorientation, libido changes</paragraph>
                  <paragraph>
                     <content styleCode="italics">Nervous system disorders:</content> headache, dizziness, tremor, dyskinesia including choreoatheetoid movements, drowsiness, convulsions, cerebral arteritis and/or occlusion, serotonin syndrome in combination with serotonergic drugs, migraine, motor and verbal tics</paragraph>
                  <paragraph>
                     <content styleCode="italics">Eye disorders: </content>blurred vision, difficulties in visual accommodation, diplopia, mydriasis, increased intraocular pressure</paragraph>
                  <paragraph>
                     <content styleCode="italics">Cardiac disorders:</content> tachycardia, palpitations, increased blood pressure, arrhythmias, angina pectoris, sudden cardiac death, myocardial infarction, bradycardia, extrasystole</paragraph>
                  <paragraph>
                     <content styleCode="italics">Respiratory, thoracic and mediastinal disorders: </content>cough, pharyngolaryngeal pain, dyspnea</paragraph>
                  <paragraph>
                     <content styleCode="italics">Gastrointestinal disorders:</content> dry mouth, nausea, vomiting, abdominal pain, dyspepsia, diarrhea</paragraph>
                  <paragraph>
                     <content styleCode="italics">General disorders:</content> fatigue, hyperpyrexia</paragraph>
                  <paragraph>
                     <content styleCode="italics">Hepatobiliary disorders: </content>abnormal liver function, ranging from transaminase elevation to severe hepatic injury</paragraph>
                  <paragraph>
                     <content styleCode="italics">Skin and subcutaneous tissue disorders:</content> hyperhidrosis, pruritus, urticaria, exfoliative dermatitis, scalp hair loss, erythema multiforme rash, thrombocytopenic purpura angioneurotic edema, erythema, fixed drug eruption</paragraph>
                  <paragraph>
                     <content styleCode="italics">Musculoskeletal and connective tissue disorders: </content>arthralgia, muscle cramps, rhabdomyolysis, myalgia, muscle twitching</paragraph>
                  <paragraph>
                     <content styleCode="italics">Renal and urinary disorders: </content>hematuria</paragraph>
                  <paragraph>
                     <content styleCode="italics">Reproductive system and breast disorders: </content>gynecomastia</paragraph>
                  <paragraph>
                     <content styleCode="italics">Urogenital disorders:</content> priapism</paragraph>
                  <paragraph>
                     <content styleCode="italics">Vascular disorders: </content>peripheral coldness, Raynaud’s phenomenon</paragraph>
                  <paragraph>
                     <content styleCode="italics"> Investigations:</content> weight loss</paragraph>
               </text>
               <effectiveTime value="20231214"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Common adverse reactions: tachycardia, palpitations, headache, insomnia, anxiety, hyperhidrosis, weight loss, decreased appetite, dry mouth, nausea, and abdominal pain. (<linkHtml href="#LINK_eb8a0e30-63ca-4ced-84b8-8c5655f401dc">6</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS contact Tris Pharma, Inc., at (732) 940 0358 or FDA at 1-800-FDA-1088 or </content>
                           <content styleCode="bold">
                              <content styleCode="italics">
                                 <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</linkHtml>
                              </content>
                           </content>
                           <content styleCode="bold">.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_5a356f49-8ad4-439a-927c-8ba01b943f01">
               <id root="3357eaea-ef2a-4a9c-8540-e3c7e8621bde"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">7 DRUG INTERACTIONS</content>
               </title>
               <text/>
               <effectiveTime value="20231212"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Antihypertensive Drugs: Monitor blood pressure. Adjust dosage of antihypertensive drug as needed. (<linkHtml href="#LINK_5e6d21db-0510-491c-be41-1de44f8fc0ff">7.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_5e6d21db-0510-491c-be41-1de44f8fc0ff">
                     <id root="b2bc64e2-efcb-4bea-ba41-6be5c92426c1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.1 Clinically Important Drug Interactions
with Methylphenidate Hydrochloride Oral Solution</content>
                     </title>
                     <text>
                        <paragraph>Table 1 presents clinically important drug interactions with methylphenidate hydrochloride oral solution.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 1:          Clinically Important Drug Interactions with Methylphenidate Hydrochloride Oral Solution</content>
                        </paragraph>
                        <table cellspacing="0" cellpadding="0" border="1">
                           <col width="1pt"/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td colspan="2">
                                    <paragraph>Monoamine Oxidase Inhibitors (MAOI)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="italics">Clinical Impact:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Concomitant use of MAOIs and CNS stimulants, including methylphenidate hydrochloride oral solution, can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure <content styleCode="italics">[see Contraindications (</content>
                                       <content styleCode="italics">
                                          <linkHtml href="#LINK_cf0d4f74-036e-4cee-856c-f1616c7f0274">4</linkHtml>
                                       </content>
                                       <content styleCode="italics">)]</content>.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="italics">Intervention:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Concomitant use of methylphenidate hydrochloride oral solution with monoamine oxidase inhibitors (MAOIs) or within 14 days after discontinuing MAOI treatment is contraindicated.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Antihypertensive Drugs</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="italics">Clinical Impact:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Methylphenidate hydrochloride oral solution may decrease the effectiveness of drugs used to treat hypertension <content styleCode="italics">[see Warnings and Precautions (</content>
                                       <content styleCode="italics">
                                          <linkHtml href="#LINK_8ee60d7b-2bac-45d4-b0f8-6337633f9058">5.3</linkHtml>
                                       </content>
                                       <content styleCode="italics">)]</content>.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="italics">Intervention:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Monitor blood pressure and adjust the dosage of the antihypertensive drug as needed.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Halogenated Anesthetics</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="italics">Clinical Impact:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Concomitant use of halogenated anesthetics and methylphenidate hydrochloride oral solution may increase the risk of sudden blood pressure and heart rate increase during surgery.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="italics">Intervention:</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Avoid use of methylphenidate hydrochloride oral solution in patients being treated with anesthetics on the day of surgery.</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">Risperidone</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="italics">Clinical Impact:</content>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Combined use of methylphenidate with risperidone when there is a change, whether an increase or decrease, in dosage of either or both medications, may increase the risk of extrapyramidal symptoms (EPS).</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <content styleCode="italics">Intervention:</content>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">Monitor for signs of EPS. </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                     </text>
                     <effectiveTime value="20231212"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_6d478e21-8bed-4e78-829c-ae6efec2aa0a">
               <id root="ef2285d9-42b4-49c3-bfd8-4aa8980d81c8"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text/>
               <effectiveTime value="20231212"/>
               <component>
                  <section ID="LINK_3821ef22-961c-410a-a0d2-1900568edfd9">
                     <id root="b4c3ff26-addd-42e4-bbd4-67d8d669f740"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>
                        <content styleCode="bold">8.1 Pregnancy</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Exposure Registry</content>
                        </paragraph>
                        <paragraph>There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ADHD medications, including methylphenidate hydrochloride oral solution, during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychostimulants at 1-866-961-2388.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Published studies and postmarketing reports on methylphenidate use during pregnancy have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. There may be risks to the fetus associated with the use of CNS stimulants use during pregnancy <content styleCode="italics">(see <linkHtml href="#LINK_119beb61-f5c7-4815-9351-82af485c63c1">Clinical Considerations</linkHtml>)</content>. </paragraph>
                        <paragraph>No effects on morphological development were observed in embryo-fetal development studies with oral administration of methylphenidate to pregnant rats and rabbits during organogenesis at doses up to 12 and 19 times, respectively, the maximum recommended human dose (MRHD) of 60 mg/day given to adults on a mg/m<sup>2</sup> basis. However, spina bifida was observed in rabbits at a dose 65 times the MRHD given to adults. A decrease in pup body weight was observed in a pre- and post-natal development study with oral administration of methylphenidate to rats throughout pregnancy and lactation at doses 7 times the MRHD given to adults <content styleCode="italics">(see <linkHtml href="#LINK_89f16eb2-f758-4e89-9ef5-84ac1f7d5676">Data</linkHtml>)</content>. </paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                     </text>
                     <effectiveTime value="20231212"/>
                     <component>
                        <section ID="LINK_119beb61-f5c7-4815-9351-82af485c63c1">
                           <id root="c2439739-c5eb-4f29-8ca5-a9edd494a375"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Clinical Considerations</content>
                           </title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Fetal/Neonatal Adverse Reactions</content>
                              </paragraph>
                              <paragraph>CNS stimulants, such as methylphenidate hydrochloride oral solution, can cause vasoconstriction and thereby decrease placental perfusion. No fetal and/or neonatal adverse reactions have been reported with the use of therapeutic doses of methylphenidate during pregnancy; however, premature delivery and low birth weight infants have been reported in amphetamine-dependent mothers.</paragraph>
                           </text>
                           <effectiveTime value="20231212"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_89f16eb2-f758-4e89-9ef5-84ac1f7d5676">
                           <id root="75de5067-a4f8-42bc-a204-688176a2f159"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Data</content>
                           </title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Animal Data</content>
                              </paragraph>
                              <paragraph>In embryo-fetal development studies conducted in rats and rabbits, methylphenidate was administered orally at doses of up to 75 and 200 mg/kg/day, respectively, during the period of organogenesis. Malformations (increased incidence of fetal spina bifida) were observed in rabbits at the highest dose, which is approximately 65 times the MRHD of 60 mg/day given to adults on a mg/m<sup>2</sup> basis. The no effect level for embryo-fetal development in rabbits was 60 mg/kg/day (19 times the MRHD given to adults on a mg/m<sup>2</sup> basis). There was no evidence of morphological development effects in rats, although increased incidences of fetal skeletal variations were seen at the highest dose level (12 times the MRHD of 60 mg/day given to adults on a mg/m<sup>2</sup> basis), which was also maternally toxic. The no effect level for embryo-fetal development in rats was 25 mg/kg/day (4 times the MRHD on a mg/m<sup>2 </sup>basis). When methylphenidate was administered to rats throughout pregnancy and lactation at doses of up to 45 mg/kg/day, offspring body weight gain was decreased at the highest dose (7 times the MRHD of 60 mg/day given to adults on a mg/m<sup>2</sup> basis), but no other effects on postnatal development were observed. The no effect level for pre- and postnatal development in rats was 15 mg/kg/day (~2 times the MRHD given to adults on a mg/m<sup>2</sup> basis).</paragraph>
                           </text>
                           <effectiveTime value="20231212"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="LINK_064a9304-dfa4-4ab4-a016-5e6d2889b2f7">
                     <id root="3065a2fa-ead2-4c2e-928b-80f819136504"/>
                     <code code="34079-4" codeSystem="2.16.840.1.113883.6.1" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <title>
                        <content styleCode="bold">8.2 Lactation</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Limited published literature, based on milk sampling from seven mothers reports that methylphenidate is present in human milk, which resulted in infant doses of 0.16% to 0.7% of the maternal weight-adjusted dosage and a milk/plasma ratio ranging between 1.1 and 2.7. There are no reports of adverse effects on the breastfed infant and no effects on milk production. Long-term neurodevelopmental effects on infants from stimulant exposure are unknown. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for methylphenidate hydrochloride oral solution and any potential adverse effects on the breastfed infant from methylphenidate hydrochloride oral solution or from the underlying maternal condition.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>Monitor breastfeeding infants for adverse reactions, such as agitation, insomnia, anorexia, and reduced weight gain.</paragraph>
                     </text>
                     <effectiveTime value="20210826"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_f9b81963-404c-460a-8520-dda49e563fd9">
                     <id root="3ad2759c-4f0e-4ee2-bb66-8fc9a126e224"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.4 Pediatric Use</content>
                     </title>
                     <text>
                        <paragraph>The safety and effectiveness of methylphenidate hydrochloride oral solution for the treatment of ADHD have been established in pediatric patients six years of age and older. The safety and effectiveness of methylphenidate hydrochloride oral solution in pediatric patients under six years of age have not been established. The long-term efficacy of methylphenidate in pediatric patients has not been established.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Long-Term Suppression of Growth </content>
                        </paragraph>
                        <paragraph>Growth should be monitored during treatment with stimulants, including methylphenidate hydrochloride oral solution. Pediatric patients who are not growing or gaining weight as expected may need to have their treatment interrupted <content styleCode="italics">[see Warnings and Precautions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_8be87854-d140-470f-bbea-ead5d9232af2">5.6</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Juvenile Animal Toxicity Data</content>
                        </paragraph>
                        <paragraph>In a study conducted in young rats, methylphenidate was administered orally at doses of up to 100 mg/kg/day for 9 weeks, starting early in the postnatal period (postnatal Day 7) and continuing through sexual maturity (postnatal Week 10). When these animals were tested as adults (postnatal Weeks 13-14), decreased spontaneous locomotor activity was observed in males and females previously treated with 50 mg/kg/day (approximately 4 times the MRHD of 60 mg/day given to children on a mg/m<sup>2</sup> basis) or greater, and a deficit in the acquisition of a specific learning task was seen in females exposed to the highest dose (8 times the MRHD given to children on a mg/m<sup>2</sup> basis). The no effect level for juvenile neurobehavioral development in rats (5 mg/kg/day) is less than the MRHD given to children on a mg/m<sup>2 </sup>basis. The clinical significance of the long-term behavioral effects observed in rats is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20231212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_e6bd1ee9-b6f8-406a-ab83-cfd8fe8560dd">
                     <id root="57dd58fe-f1fc-489b-997e-6a4b38718620"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.5 Geriatric Use</content>
                     </title>
                     <text>
                        <paragraph>Methylphenidate hydrochloride oral solution has not been studied in the geriatric population.</paragraph>
                     </text>
                     <effectiveTime value="20210826"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_c4b1b091-a3f1-4515-a694-2b5cef6694bf">
               <id root="afd68be0-b2de-4f43-be54-9ed0eba9d245"/>
               <code code="42227-9" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG ABUSE AND DEPENDENCE SECTION"/>
               <title>
                  <content styleCode="bold">9 DRUG ABUSE AND DEPENDENCE</content>
               </title>
               <text/>
               <effectiveTime value="20231212"/>
               <component>
                  <section ID="LINK_f3022a90-1ab4-42b1-b798-2996ea3ce240">
                     <id root="e7a7fc90-ea7d-4103-bb0b-df209e5868d7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">9.1 Controlled
Substance</content>
                     </title>
                     <text>
                        <paragraph>Methylphenidate hydrochloride oral solution contains methylphenidate hydrochloride, a Schedule II controlled substance.</paragraph>
                     </text>
                     <effectiveTime value="20210826"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_5fd1405d-143a-439f-a237-b2315c293c33">
                     <id root="2baf50ff-dd40-42ba-8770-049b91e19446"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">9.2 Abuse</content>
                     </title>
                     <text>
                        <paragraph>Methylphenidate hydrochloride oral solution has a high potential for abuse and misuse which can lead to the development of a substance use disorder, including addiction <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_3b3b21c5-29f6-4f62-88af-5ae5837a4bd1">5.1</linkHtml>)].</content> Methylphenidate hydrochloride oral solution can be diverted for non medical use into illicit channels or distribution.</paragraph>
                        <paragraph> Abuse is the intentional non-therapeutic use of a drug, even once, to achieve a desired psychological or physiological effect. Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a healthcare provider or for whom it was not prescribed. Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence. </paragraph>
                        <paragraph>Misuse and abuse of methylphenidate may cause increased heart rate, respiratory rate, or blood pressure; sweating; dilated pupils; hyperactivity; restlessness; insomnia; decreased appetite; loss of coordination; tremors; flushed skin; vomiting; and/or abdominal pain. Anxiety, psychosis, hostility, aggression, and suicidal or homicidal ideation have also been observed with CNS stimulants abuse and/or misuse. Misuse and abuse of CNS stimulants, including methylphenidate hydrochloride oral solution, can result in overdose and death <content styleCode="italics">[see Overdosage (</content>
                           <content styleCode="italics">
                              <linkHtml href="#LINK_bc3ddadb-3b0b-4cf1-b5d0-12ff357b4879">10</linkHtml>
                           </content>
                           <content styleCode="italics">)]<content styleCode="italics">, </content>
                           </content>and this risk is increased with higher doses and or unapproved methods of administration, such as snorting or injection.</paragraph>
                     </text>
                     <effectiveTime value="20231212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_6fcbeff3-254f-49c3-82f0-5a5eff279d8b">
                     <id root="960a618c-3dac-4088-b941-85076b24b647"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">9.3 Dependence</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Physical Dependence</content>
                        </paragraph>
                        <paragraph>Methylphenidate hydrochloride oral solution may produce physical dependence. Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug. </paragraph>
                        <paragraph>Withdrawal signs and symptoms after abrupt discontinuation or dose reduction following prolonged use of CNS stimulants include dysphoric mood; depression; fatigue; vivid, unpleasant dreams; insomnia or hypersomnia; increased appetite; and psychomotor retardation or agitation.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Tolerance</content>
                        </paragraph>
                        <paragraph>Methylphenidate hydrochloride oral solution may produce tolerance. Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose).</paragraph>
                     </text>
                     <effectiveTime value="20231212"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_bc3ddadb-3b0b-4cf1-b5d0-12ff357b4879">
               <id root="86aa273e-0b9f-407a-9f17-5c393589e2d4"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>
                  <content styleCode="bold">10 OVERDOSAGE</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Clinical Effects of Overdose</content>
                  </paragraph>
                  <paragraph>Overdose of CNS stimulants is characterized by the following sympathomimetic effects:</paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>Cardiovascular effects including tachyarrhythmias, and hypertension or hypotension. Vasospasm, myocardial infarction, or aortic dissection may precipitate sudden cardiac death. Takotsubo cardiomyopathy may develop.</item>
                  </list>
                  <list listType="unordered" styleCode="Disk">
                     <item>CNS effects including psychomotor agitation, confusion, and hallucinations. Serotonin syndrome, seizures, cerebral vascular accidents, and coma may occur.</item>
                  </list>
                  <list listType="unordered" styleCode="Disk">
                     <item>Life-threatening hyperthermia (temperatures greater than 104°F) and rhabdomyolysis may develop.</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Overdose Management</content>
                  </paragraph>
                  <paragraph>Consider the possibility of multiple drug ingestion. Because methylphenidate has a large volume of distribution and is rapidly metabolized, dialysis is not useful. Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.</paragraph>
               </text>
               <effectiveTime value="20231212"/>
            </section>
         </component>
         <component>
            <section ID="LINK_fbac5b4a-b11d-470f-9e1b-b21e8685d2d1">
               <id root="17be14f9-6c90-4cd3-af2f-b15efbb643c7"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>
                  <content styleCode="bold">11 DESCRIPTION</content>
               </title>
               <text>
                  <paragraph>Methylphenidate hydrochloride oral solution is a CNS stimulant available as 5 mg/5 mL and 10 mg/5 mL strengths for oral administration. Chemically, Methylphenidate hydrochloride is (<content styleCode="italics">d,l </content>racemic) methyl α-phenyl-2-piperidineacetate hydrochloride, and its structural formula is:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>Methylphenidate hydrochloride, USP is a white, odorless, fine crystalline powder. Its solutions are acid to litmus. It is freely soluble in water and in methanol, soluble in alcohol, and slightly soluble in chloroform and in acetone.</paragraph>
                  <paragraph>Each mL of methylphenidate hydrochloride oral solution 5 mg/5 mL contains 1 mg of methylphenidate hydrochloride, USP.</paragraph>
                  <paragraph>Each mL of methylphenidate hydrochloride oral solution 10 mg/5 mL contains 2 mg of methylphenidate hydrochloride, USP.</paragraph>
                  <paragraph>In addition, methylphenidate hydrochloride oral solution also contains the following inactive ingredients: artificial grape flavor, glycerin, hydrochloric acid, polyethylene glycol 1450, and purified water.</paragraph>
               </text>
               <effectiveTime value="20231212"/>
            </section>
         </component>
         <component>
            <section ID="LINK_fbc62e38-7f9b-4ecb-9bdb-56ff69dbb556">
               <id root="c63bf170-b7e7-415a-82ed-f8f8b828475f"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">12 CLINICAL PHARMACOLOGY</content>
               </title>
               <text/>
               <effectiveTime value="20231212"/>
               <component>
                  <section ID="LINK_d8ba8f10-0a97-4bd9-9f98-1bf4a761b927">
                     <id root="fe35d1a9-b93b-4f8f-94cd-d17dea0c53bf"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>
                        <content styleCode="bold">12.1 Mechanism of Action</content>
                     </title>
                     <text>
                        <paragraph>Methylphenidate hydrochloride is a central nervous system (CNS) stimulant. The mode of therapeutic action in ADHD is not known.</paragraph>
                     </text>
                     <effectiveTime value="20210826"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_e0122653-6b51-4fd0-a83f-05261004d253">
                     <id root="dab3c6c2-ef4c-49bb-b24f-870954e20a69"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>
                        <content styleCode="bold">12.2 Pharmacodynamics</content>
                     </title>
                     <text>
                        <paragraph>Methylphenidate is a racemic mixture comprised of the <content styleCode="italics">d</content>- and <content styleCode="italics">l-threo</content> enantiomers. The <content styleCode="italics">d-threo</content> enantiomer is more pharmacologically active than the <content styleCode="italics">l</content>-<content styleCode="italics">threo</content> enantiomer. Methylphenidate blocks the reuptake of norepinephrine and dopamine into the presynaptic neuron and increases the release of these monoamines into the extraneuronal space.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Cardiac Electrophysiology</content>
                        </paragraph>
                        <paragraph>A formal QT study has not been conducted in subjects taking methylphenidate hydrochloride oral solution.</paragraph>
                        <paragraph>The effect of dexmethylphenidate, the pharmacologically active d-enantiomer of methylphenidate hydrochloride oral solution, on the QT interval was evaluated in a double-blind, placebo- and open-label active (moxifloxacin)-controlled study following single doses of 40 mg dexmethylphenidate hydrochloride extended-release capsule in 75 healthy volunteers. Electrocardiograms were collected up to 12 hours postdose. Frederica’s method for heart rate correction was employed to derive the corrected QT interval (QTcF). The maximum mean prolongation of QTcF intervals was less than 5 ms, and the upper limit of the 90% confidence interval was below 10 ms for all time-matched comparisons versus placebo. This was below the threshold of clinical concern and there was no evident exposure response relationship.</paragraph>
                     </text>
                     <effectiveTime value="20210826"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_f00e677a-3f2a-4b1c-a978-5a8a2288cb5d">
                     <id root="d6e0a38c-931d-4157-8bda-1838b15bb3e3"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>
                        <content styleCode="bold">12.3 Pharmacokinetics</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Absorption</content>
                           </content>
                        </paragraph>
                        <paragraph>Following a single dose administration of 20 mg methylphenidate hydrochloride oral solution and 20 mg tablet of methylphenidate hydrochloride in healthy volunteers under fasted conditions, time to peak plasma concentration (T<sub>max</sub>) of methylphenidate was at 1 to 2 hours after dosing, and:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>The mean peak plasma concentration (C<sub>max</sub>) of methylphenidate was 9.1 ng/mL and 9.8 ng/mL, respectively.</item>
                           <item>The mean area under concentration curve (AUC) of methylphenidate was 46.7 hour*ng/mL and 50.0 hour*ng/mL, respectively.</item>
                        </list>
                        <paragraph>
                           <content styleCode="italics">Effect of Food</content>
                        </paragraph>
                        <paragraph>Ingestion of a high-fat meal with methylphenidate hydrochloride oral solution increased methylphenidate mean C<sub>max</sub> and AUC by about 13% and 25%, respectively. Time to C<sub>max</sub> (T<sub>max</sub>) was delayed by approximately 1 hour.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>Plasma protein binding is 10% to 33%. The volume of distribution was 2.65 ± 1.11 L/kg for d-methylphenidate and 1.80 ± 0.91 L/kg for l-methylphenidate.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>The mean terminal half-life (t1/2) of methylphenidate was 2.7 hours following administration of 20 mg methylphenidate hydrochloride oral solution. The systemic clearance is 0.40 ± 0.12 L/h/kg for d-methylphenidate and 0.73 ± 0.28 L/h/kg for l-methylphenidate.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>Methylphenidate is metabolized primarily by deesterification to alpha-phenyl-piperidine acetic acid (ritalinic acid), which has little or no pharmacologic activity.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>After oral dosing of radiolabeled methylphenidate in humans, about 90% of the radioactivity was recovered in urine. The main urinary metabolite was ritalinic acid, accounting for approximately 80% of the dose. </paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Specific Populations</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Male and Female Patients, Racial Groups, and Age </content>
                        </paragraph>
                        <paragraph>The effect of gender, race, and age on the pharmacokinetics of methylphenidate after methylphenidate hydrochloride oral solution administration have not been studied.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Renal Impairment</content>
                        </paragraph>
                        <paragraph>Methylphenidate hydrochloride oral solution has not been studied in patients with renal impairment. Since renal clearance is not an important route of methylphenidate clearance, renal impairment is expected to have little effect on the pharmacokinetics of methylphenidate hydrochloride oral solution.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Hepatic Impairment</content>
                        </paragraph>
                        <paragraph>Methylphenidate hydrochloride oral solution has not been studied in patients with hepatic impairment. Since methylphenidate is metabolized primarily to ritalinic acid by nonmicrosomal hydrolytic esterases that are widely distributed throughout the body, hepatic impairment is expected to have minimal effect on the pharmacokinetics of methylphenidate hydrochloride oral solution.</paragraph>
                     </text>
                     <effectiveTime value="20231212"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_821138c3-0a53-438c-b5f7-50bd650acedc">
               <id root="40c3b566-cb6f-4af6-a54a-89902adfe50c"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">13 NONCLINICAL TOXICOLOGY</content>
               </title>
               <text/>
               <effectiveTime value="20231212"/>
               <component>
                  <section ID="LINK_8292fa9d-3d67-4727-b82b-a633f7a37ddd">
                     <id root="a842d39b-2b1e-46c5-8ba6-2d37bc98a832"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>
                        <content styleCode="bold">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis</content>
                        </paragraph>
                        <paragraph>In a lifetime carcinogenicity study carried out in B6C3F1 mice, methylphenidate caused an increase in hepatocellular adenomas and, in males only, an increase in hepatoblastomas, at a daily dose of approximately 60 mg/kg/day. This dose is approximately 5 times the maximum recommended human dose (MRHD) of 60 mg/kg given to adults on a mg/m<sup>2</sup> basis. Hepatoblastoma is a relatively rare rodent malignant tumor type. There was no increase in total malignant hepatic tumors. The mouse strain used is sensitive to the development of hepatic tumors, and the significance of these results to humans is unknown.</paragraph>
                        <paragraph>Methylphenidate did not cause any increase in tumors in a lifetime carcinogenicity study carried out in F344 rats; the highest dose used was approximately 45 mg/kg/day, which is approximately 7 times the MRHD (adults) on a mg/m<sup>2</sup> basis.</paragraph>
                        <paragraph>In a 24-week carcinogenicity study in the transgenic mouse strain p53+/-, which is sensitive to genotoxic carcinogens, there was no evidence of carcinogenicity. Male and female mice were fed diets containing the same concentration of methylphenidate as in the lifetime carcinogenicity study; the high-dose groups were exposed to 60 to 74 mg/kg/day of methylphenidate.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                        </paragraph>
                        <paragraph>Methylphenidate was not mutagenic in the <content styleCode="italics">in vitro</content> Ames reverse mutation assay, in the <content styleCode="italics">in vitro</content> mouse lymphoma cell forward mutation assay, or in the <content styleCode="italics">in vitro</content> chromosomal aberration assay using human lymphocytes. Sister chromatid exchanges and chromosome aberrations were increased, indicative of a weak clastogenic response, in an <content styleCode="italics">in vitro</content> assay in cultured Chinese Hamster Ovary (CHO) cells. Methylphenidate was negative <content styleCode="italics">in vivo</content> in males and females in the mouse bone marrow micronucleus assay.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>No human data on the effect of methylphenidate on fertility are available. Methylphenidate did not impair fertility in male or female mice that were fed diets containing the drug in an 18-week continuous breeding study. The study was conducted at doses up to 160 mg/kg/day, approximately 13 times the maximum recommended human dose of 60 mg/day given to adults on a mg/m<sup>2 </sup>basis.</paragraph>
                     </text>
                     <effectiveTime value="20231212"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_0ef6a488-e212-44dd-be41-742b14459d17">
               <id root="f2a37570-913f-427b-bf01-87b553520519"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>
                  <content styleCode="bold">16 HOW SUPPLIED/STORAGE AND HANDLING</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="underline">How Supplied</content>
                  </paragraph>
                  <paragraph>Methylphenidate hydrochloride oral solution 5 mg per 5 mL is a colorless, grape flavored liquid. It is supplied in bottles of 500 mL, NDC 72162-2040-5.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Storage and Handling</content>
                  </paragraph>
                  <paragraph>Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].</paragraph>
                  <paragraph>Dispense in tight container with child-resistant closure.</paragraph>
                  <paragraph>Repackaged/Relabeled by:<br/>Bryant Ranch Prepack, Inc.<br/>Burbank, CA 91504</paragraph>
               </text>
               <effectiveTime value="20240416"/>
            </section>
         </component>
         <component>
            <section ID="LINK_0d862fa7-dbc0-4fd1-ab75-40a5c1729a60">
               <id root="3a7e77b9-0f89-42c4-818e-ae91a35e576f"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>
                  <content styleCode="bold">17 PATIENT COUNSELING INFORMATION</content>
               </title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (<linkHtml href="#LINK_8c1a5e9d-b9c8-45cb-a4da-2edf7731b543">Medication Guide</linkHtml>).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Abuse, Misuse, and Addiction</content>
                  </paragraph>
                  <paragraph>Educate patients and their families about the risks of abuse, misuse, and addiction of methylphenidate hydrochloride oral solution, which can lead to overdose and death, and proper disposal of any unused drug <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_3b3b21c5-29f6-4f62-88af-5ae5837a4bd1">5.1</linkHtml>), Drug Abuse and Dependence (<linkHtml href="#LINK_5fd1405d-143a-439f-a237-b2315c293c33">9.2</linkHtml>), Overdosage (<linkHtml href="#LINK_bc3ddadb-3b0b-4cf1-b5d0-12ff357b4879">10</linkHtml>)]</content>. Advise patients to store methylphenidate hydrochloride oral solution in a safe place, preferably locked, and instruct patients to not give methylphenidate hydrochloride oral solution to anyone else.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Risks to Patients with Serious Cardiac Disease</content>
                  </paragraph>
                  <paragraph>Advise patients that there are potential risks to patients with serious cardiac disease, including sudden death, with methylphenidate hydrochloride oral solution use. Instruct patients to contact a healthcare provider immediately if they develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_87a0e526-65fe-43e4-9fe6-69c7a31ef9cb">5.2</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Increased Blood Pressure and Heart Rate </content>
                  </paragraph>
                  <paragraph>Instruct patients that methylphenidate hydrochloride oral solution can elevate blood pressure and heart rate <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_8ee60d7b-2bac-45d4-b0f8-6337633f9058">5.3</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Psychiatric Adverse Reactions</content>
                  </paragraph>
                  <paragraph>Advise patients that methylphenidate hydrochloride oral solution, at recommended doses, can cause psychotic or manic symptoms, even in patients without prior history of psychotic symptoms or mania <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_e1d6e8c2-3cd1-470d-86f6-d848b148569e">5.4</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Priapism</content>
                  </paragraph>
                  <paragraph>Advise patients of the possibility of painful or prolonged penile erections (priapism). Instruct the patient to seek immediate medical attention in the event of priapism <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_9dfd199a-670f-4709-8ce5-85e3e9c5a04f">5.5</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Circulation Problems in Fingers and Toes (Peripheral Vasculopathy, Including Raynaud’s Phenomenon)</content>
                  </paragraph>
                  <paragraph>Instruct patients about the risk of peripheral vasculopathy, including Raynaud’s phenomenon, and associated signs and symptoms: fingers or toes may feel numb, cool, painful, and/or may change color from pale, to blue, to red.</paragraph>
                  <paragraph>Instruct patients to report to their physician any new numbness, pain, skin color change, or sensitivity to temperature in fingers or toes. Instruct patients to call their physician immediately with any signs of unexplained wounds appearing on fingers or toes while taking methylphenidate hydrochloride oral solution. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for certain patients <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_8be87854-d140-470f-bbea-ead5d9232af2">5.6</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Long-Term Suppression of Growth in Pediatric Patients</content>
                  </paragraph>
                  <paragraph>Advise patients that methylphenidate hydrochloride oral solution may cause slowing of growth and weight loss in pediatric patients <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_99d54a3a-fe88-4f54-91b0-02e8d8155e0e">5.7</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Increased Intraocular Pressure (IOP) and Glaucoma</content>
                  </paragraph>
                  <paragraph>Advise patients that IOP and glaucoma may occur during treatment with methylphenidate hydrochloride oral solution <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_4bb472b7-1eb3-486b-9601-b519ffc4be81">5.9</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Motor and Verbal Tics, and Worsening of Tourette’s Syndrome</content>
                  </paragraph>
                  <paragraph>Advise patients that motor and verbal tics and worsening of Tourette’s syndrome may occur during treatment with methylphenidate hydrochloride oral solution. Instruct patients to notify their healthcare provider if emergence of new tics or worsening of tics or Tourette’s syndrome occurs <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_3a521fb2-da03-4234-a43c-8334c70f4306">5.10</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Pregnancy Exposure Registry</content>
                  </paragraph>
                  <paragraph>Inform patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in patients exposed to methylphenidate hydrochloride oral solution during pregnancy <content styleCode="italics">[see Use in Specific Populations (</content>
                     <content styleCode="italics">
                        <linkHtml href="#LINK_3821ef22-961c-410a-a0d2-1900568edfd9">8.1</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>Manufactured by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Tris Pharma Inc.</content>
                  </paragraph>
                  <paragraph>Monmouth Junction, NJ 08852</paragraph>
                  <paragraph>
                     <linkHtml href="#www.trispharma.com">www.trispharma.com</linkHtml>
                  </paragraph>
                  <paragraph>LB8477</paragraph>
                  <paragraph>Rev. 03</paragraph>
                  <paragraph>12/2023</paragraph>
               </text>
               <effectiveTime value="20231212"/>
            </section>
         </component>
         <component>
            <section ID="LINK_8c1a5e9d-b9c8-45cb-a4da-2edf7731b543">
               <id root="991b9f1f-51a9-44d5-bbf3-95ee17eb7031"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <title>
                  <content styleCode="bold">MEDICATION GUIDE</content>
               </title>
               <text>
                  <table cellspacing="0" cellpadding="0" border="1">
                     <col width="1pt"/>
                     <col/>
                     <tbody>
                        <tr>
                           <td colspan="2">
                              <paragraph>
                                 <content styleCode="bold">Methylphenidate Hydrochloride Oral Solution CII</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">(METH il FEN i date)</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">5 mg/5 mL and 10 mg/5 mL</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Rx only</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What is the most important information I should know about Methylphenidate Hydrochloride Oral Solution?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Methylphenidate Hydrochloride Oral Solution may cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Abuse<content styleCode="bold">, misuse, and addiction.</content>
                                    </content> Methylphenidate Hydrochloride Oral Solution has a high chance for abuse and misuse and may lead to substance use problems, including addiction. Misuse and abuse of Methylphenidate Hydrochloride Oral Solution, other methylphenidate containing medicines, and amphetamine containing medicines, can lead to overdose and death. The risk of overdose and death is increased with higher doses of Methylphenidate Hydrochloride Oral Solution or when it is used in ways that are not approved, such as snorting or injection.
                <list listType="unordered" styleCode="Circle">
                                       <item>Your healthcare provider should check you or your child’s risk for abuse, misuse, and addiction before starting treatment with Methylphenidate Hydrochloride Oral Solution and will monitor you or your child during treatment.</item>
                                       <item>Methylphenidate Hydrochloride Oral Solution may lead to physical dependence after prolonged use, even if taken as directed by your healthcare provider.</item>
                                       <item>Do not give Methylphenidate Hydrochloride Oral Solution to anyone else. See <content styleCode="bold">“What is Methylphenidate Hydrochloride Oral Solution?”</content> for more information.</item>
                                       <item>Keep Methylphenidate Hydrochloride Oral Solution in a safe place and properly dispose of any unused medicine. See <content styleCode="bold">“How should I store Methylphenidate Hydrochloride Oral Solution?”</content> for more information.</item>
                                       <item>Tell your healthcare provider if you or your child have ever abused or been dependent on alcohol, prescription medicines, or street drugs.</item>
                                    </list>
                                 </item>
                                 <item>
                                    <content styleCode="bold">
                                       <content styleCode="bold">Risks for people with serious heart disease. </content>
                                    </content>Sudden death has happened in people who have heart defects or other serious heart disease.
                <paragraph>Your healthcare provider should check you or your child carefully for heart problems before starting treatment with Methylphenidate Hydrochloride Oral Solution. Tell your healthcare provider if you or your child have any heart problems, heart disease, or heart defects.</paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Call your healthcare provider or go to the nearest hospital emergency room right away if you or your child have any signs of heart problems such as chest pain, shortness of breath, or fainting during treatment with Methylphenidate Hydrochloride Oral Solution.</content>
                                    </paragraph>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Increased blood pressure and heart rate.</content>
                                    <content styleCode="bold">
                                       <br/>
                                    </content>Your healthcare provider should check your or your child’s blood pressure and heart rate regularly during treatment with Methylphenidate Hydrochloride Oral Solution.</item>
                                 <item>
                                    <content styleCode="bold">Mental (psychiatric) problems, including:</content>
                                 </item>
                              </list>
                              <list listType="unordered" styleCode="Circle">
                                 <item>new or worse behavior and thought problems</item>
                                 <item>new or worse bipolar illness</item>
                                 <item>new psychotic symptoms (such as hearing voices, or seeing or believing things that are not real) or new manic symptoms</item>
                              </list>
                              <paragraph>Tell your healthcare provider about any mental problems you or your child have, or about a family history of suicide, bipolar illness, or depression.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Call your healthcare provider right away if you or your child have any new or worsening mental symptoms or problems during treatment with Methylphenidate Hydrochloride Oral Solution, especially hearing voices, seeing or believing things that are not real, or new manic symptoms.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What is Methylphenidate Hydrochloride Oral Solution?</content>
                              </paragraph>
                              <paragraph>Methylphenidate Hydrochloride Oral Solution is a prescription medicine used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in people 6 years of age and older. Methylphenidate Hydrochloride Oral Solution may help increase attention and decrease impulsiveness and hyperactivity in people with ADHD.</paragraph>
                              <paragraph>It is not known if Methylphenidate Hydrochloride Oral Solution is safe and effective for use in children under 6 years of age.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Methylphenidate Hydrochloride Oral Solution is a federally controlled substance (CII) because it contains methylphenidate that can be a target for people who abuse prescription medicines or street drugs.</content>
                              </paragraph>
                              <paragraph>Keep Methylphenidate Hydrochloride Oral Solution in a safe place to protect it from theft. Never give your Methylphenidate Hydrochloride Oral Solution to anyone else, because it may cause death or harm them. Selling or giving away Methylphenidate Hydrochloride Oral Solution may harm others and is against the law.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Do not take Methylphenidate Hydrochloride Oral Solution if you or your child are:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>allergic to methylphenidate hydrochloride or any of the ingredients in Methylphenidate Hydrochloride Oral Solution. See the end of this Medication Guide for a complete list of ingredients in Methylphenidate Hydrochloride Oral Solution.</item>
                                 <item>taking, or have stopped taking within the past 14 days, a medicine called a monoamine oxidase inhibitor (MAOI).</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Before taking Methylphenidate Hydrochloride Oral Solution tell your healthcare provider about all your medical conditions, including if you or your child:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>have heart problems, heart disease, heart defects, or high blood pressure</item>
                                 <item>have mental problems including psychosis, mania, bipolar illness, or depression, or have a family history of suicide, bipolar illness, or depression</item>
                              </list>
                              <list listType="unordered" styleCode="Disc">
                                 <item>have circulation problems in fingers and toes </item>
                                 <item>have eye problems, including increased pressure in your eye, glaucoma, or problems with your close-up vision (farsightedness)</item>
                                 <item>have or had repeated movements or sounds (tics) or Tourette’s syndrome, or have a family history of tics or Tourette’s syndrome</item>
                              </list>
                              <list listType="unordered" styleCode="Disc">
                                 <item>are pregnant or plan to become pregnant. It is not known if Methylphenidate Hydrochloride Oral Solution will harm the unborn baby.
                <list listType="unordered" styleCode="Circle">
                                       <item>There is a pregnancy registry for females who are exposed to Methylphenidate Hydrochloride Oral Solution during pregnancy. The purpose of the registry is to collect information about the health of females exposed to Methylphenidate Hydrochloride Oral Solution and their baby. If you or your child becomes pregnant during treatment with Methylphenidate Hydrochloride Oral Solution, talk to your healthcare provider about registering with the National Pregnancy Registry for Psychostimulants at 1-866-961-2388.</item>
                                    </list>
                                 </item>
                              </list>
                              <list listType="unordered" styleCode="Disc">
                                 <item>are breastfeeding or plan to breastfeed. Methylphenidate Hydrochloride Oral Solution passes into breast milk. Talk to your healthcare provider about the best way to feed the baby during treatment with Methylphenidate Hydrochloride Oral Solution.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Tell your healthcare provider about all the medicines that you take or your child take</content>, including prescription and over-the-counter medicines, vitamins, and herbal supplements.</paragraph>
                              <paragraph>Methylphenidate Hydrochloride Oral Solution and some medicines may interact with each other and cause serious side effects. Sometimes the doses of other medicines will need to be changed during treatment with Methylphenidate Hydrochloride Oral Solution. Your healthcare provider will decide whether Methylphenidate Hydrochloride Oral Solution can be taken with other medicines.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Especially tell your healthcare provider if you or your child take </content>a medicine used to treat depression called a monoamine oxidase inhibitor (MAOI).</paragraph>
                              <paragraph>Know the medicines that you take or your child take. Keep a list of your medicines with you to show your healthcare provider and pharmacist. <content styleCode="bold">Do not start any new medicine during treatment with Methylphenidate Hydrochloride Oral Solution without talking to your healthcare provider first.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">How should Methylphenidate Hydrochloride Oral Solution be taken?</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Take Methylphenidate Hydrochloride Oral Solution exactly as prescribed by your healthcare provider.</item>
                                 <item>Your healthcare provider may change the dose if needed.</item>
                              </list>
                              <list listType="unordered" styleCode="Disk">
                                 <item>
                                    <content styleCode="bold">Children 6 years of age and older:</content>
                                 </item>
                              </list>
                              <list listType="unordered" styleCode="Circle">
                                 <item>Take Methylphenidate Hydrochloride Oral Solution by mouth 2 times a day before breakfast and lunch, 30 to 45 minutes before a meal, as prescribed by your healthcare provider.
                </item>
                              </list>
                              <list listType="unordered" styleCode="Disk">
                                 <item>
                                    <content styleCode="bold">Adults:</content>
                                    <list listType="unordered" styleCode="Circle">
                                       <item>Take Methylphenidate Hydrochloride Oral Solution by mouth 2 or 3 times a day, 30 to 45 minutes before a meal, as prescribed by your healthcare provider.</item>
                                       <item>For adults who have sleep problems when Methylphenidate Hydrochloride Oral Solution is taken late in the day, take your last dose of Methylphenidate Hydrochloride Oral Solution before 6 p.m.</item>
                                    </list>
                                 </item>
                              </list>
                              <list listType="unordered" styleCode="Disc">
                                 <item>If you or your child take too much Methylphenidate Hydrochloride Oral Solution, call your healthcare provider or Poison Help Line at 1-800-222-1222 or go to the nearest hospital emergency room right away.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What are the possible side effects of Methylphenidate Hydrochloride Oral Solution?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Methylphenidate Hydrochloride Oral Solution may cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>See <content styleCode="bold">“What is the most important information I should know about Methylphenidate Hydrochloride Oral Solution?</content>”</item>
                                 <item>
                                    <content styleCode="bold">Painful and prolonged erections (priapism).</content> Priapism has happened in males who take products that contain methylphenidate. <content styleCode="bold">If you or your child develop priapism, get medical help right away.</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Circulation problems in fingers and toes (peripheral vasculopathy, including Raynaud’s phenomenon).</content> Signs and symptoms may include:
                <list listType="unordered" styleCode="Circle">
                                       <item>fingers or toes may feel numb, cool, painful</item>
                                       <item>fingers or toes may change color from pale, to blue, to red</item>
                                    </list>
                                    <paragraph>Tell your healthcare provider if you or your child have numbness, pain, skin color change, or sensitivity to temperature in the fingers or toes, or if you or your child have any signs of unexplained wounds appearing on fingers or toes during treatment with Methylphenidate Hydrochloride Oral Solution.</paragraph>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Slowing of growth (height and weight) in children</content>. Children should have their height and weight checked often during treatment with Methylphenidate Hydrochloride Oral Solution. Methylphenidate Hydrochloride Oral Solution treatment may be stopped if your child is not growing or gaining weight. </item>
                                 <item>
                                    <content styleCode="bold">Eye problems (increased pressure in the eye and glaucoma). </content>Call your healthcare provider right away if you or your child develop changes in your vision or eye pain, swelling, or redness.</item>
                                 <item>
                                    <content styleCode="bold">New or worsening tics or worsening Tourette’s syndrome. </content>Tell your healthcare provider if you or your child get any new or worsening tics or worsening Tourette’s syndrome during treatment with Methylphenidate Hydrochloride Oral Solution.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">The most common side effects of Methylphenidate Hydrochloride Oral Solution include:</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>increased heart rate</item>
                                 <item>headache</item>
                                 <item>anxiety</item>
                                 <item>weight loss</item>
                                 <item>dry mouth</item>
                                 <item>stomach pain</item>
                              </list>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>irregular heart beat (palpitations)</item>
                                 <item>trouble sleeping</item>
                                 <item>sweating</item>
                                 <item>decreased appetite</item>
                                 <item>nausea</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>These are not all the possible side effects of Methylphenidate Hydrochloride Oral Solution.</paragraph>
                              <paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">How should I store Methylphenidate Hydrochloride Oral Solution?</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Store Methylphenidate Hydrochloride Oral Solution at room temperature between 68°F to 77°F (20°C to 25°C).
                <paragraph>Store Methylphenidate Hydrochloride Oral Solution in a safe place, like a locked cabinet.</paragraph>
                                 </item>
                                 <item>Protect from light and moisture.</item>
                                 <item>Dispose of remaining, unused, or expired Methylphenidate Hydrochloride Oral Solution by a medicine take-back program at a U.S. Drug Enforcement Administration (DEA) authorized collection site. If no take-back program or DEA authorized collector is available, mix Methylphenidate Hydrochloride Oral Solution with an undesirable, nontoxic substance such as dirt, cat litter, or used coffee grounds to make it less appealing to children and pets. Place the mixture in a container such as a sealed plastic bag and throw away Methylphenidate Hydrochloride Oral Solution in the household trash. Visit <linkHtml href="https://www.fda.gov/drugs/ensuring-safe-use-medicine/safe-disposal-medicines">www.fda.gov/drugdisposal</linkHtml> for additional information on disposal of unused medicines.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Keep Methylphenidate Hydrochloride Oral Solution and all medicines out of the reach of children.</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">General information about the safe and effective use of Methylphenidate Hydrochloride Oral Solution.</content>
                              </paragraph>
                              <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Methylphenidate Hydrochloride Oral Solution for a condition for which it was not prescribed. Do not give Methylphenidate Hydrochloride Oral Solution to other people, even if they have the same symptoms. It may harm them and it is against the law. You can ask your healthcare provider or pharmacist for information about Methylphenidate Hydrochloride Oral Solution that is written for healthcare professionals.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What are the ingredients in Methylphenidate Hydrochloride Oral Solution?</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Active Ingredient:</content> methylphenidate hydrochloride, USP</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Inactive Ingredients: </content>artificial grape flavor, glycerin, hydrochloric acid, polyethylene glycol 1450, and purified water.</paragraph>
                              <paragraph>Manufactured by:</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Tris Pharma, Inc.</content>
                              </paragraph>
                              <paragraph>Monmouth Junction, NJ 08852</paragraph>
                              <paragraph>For more information about Methylphenidate Hydrochloride Oral Solution contact Tris Pharma, Inc at 732-940-0358 or go to <linkHtml href="#www.trispharma.com">www.trispharma.com</linkHtml>.</paragraph>
                              <paragraph>LB8478</paragraph>
                              <paragraph>Rev. 03</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Medication Guide has been approved by the U.S. Food and Drug Administration.      Revised: 12/2023</paragraph>
                  <br/>
               </text>
               <effectiveTime value="20231215"/>
            </section>
         </component>
         <component>
            <section>
               <id root="d4a33c79-c44d-4017-8fbe-56e0a31806ce"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>Methylphenidate HCl Sol (CII) 5 mg/mL #500</paragraph>
                  <renderMultiMedia referencedObject="mm63629"/>
               </text>
               <effectiveTime value="20250314"/>
               <component>
                  <observationMedia ID="mm63629">
                     <text>Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="lbl721622040.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>